Literature DB >> 25850777

Chronic ischemic viable myocardium in man: Aspects of dedifferentiation.

J Ausma1, G Schaart1, F Thoné2, B Shivalkar3, W Flameng3, C Depré4, J L Vanoverschelde4, F Ramaekers1, M Borgers5.   

Abstract

Histologic analysis of biopsies derived from patients with chronic dysfunctional but viable (hibernating) myocardium showed characteristic cell alterations. These changes consisted of a partial to complete loss of sarcomeres, accumulation of glycogen, and disorganization and loss of sarcoplasmic reticulum. Most of the adaptive changes that these affected cells undergo are suggestive of dedifferentiation. In the present study the expression and organizational pattern of contractile and cytoskeletal proteins such as titin, cardiotin, and α-smooth muscle actin were assessed in hibernating and normal myocardium because the expression and organization of these constituents have been related to certain stages of cardiomyocyte differentiation. In normal cells titin shows a cross-striated staining pattern, whereas cardiotin displays a fibrillar array, parallel to the sarcomeres. α-Smooth muscle actin is not expressed in adult cardiomyocytes. The expression of titin in a punctated pattern and the marked decrease to virtual absence of cardiotin in hibernating cardiomyocytes speak in favor of an embryonic phenotype of these cells. The re-expression of α-smooth muscle actin in hibernating cells strongly supports this hypothesis. The observations on three different structural proteins of heart muscle suggest that hibernating myocardium acquired aspects of muscle cell dedifferentiation.

Entities:  

Year:  1995        PMID: 25850777     DOI: 10.1016/1054-8807(94)00028-p

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  17 in total

Review 1.  Use of cardiac magnetic resonance to assess viability.

Authors:  Anja Wagner; Heiko Mahrholdt; Raymond J Kim; Robert M Judd
Journal:  Curr Cardiol Rep       Date:  2005-01       Impact factor: 2.931

Review 2.  Hibernating myocardium.

Authors:  John M Canty; James A Fallavollita
Journal:  J Nucl Cardiol       Date:  2005 Jan-Feb       Impact factor: 5.952

3.  Hibernating myocardium: Programmed cell survival or programmed cell death?

Authors:  Marcel Borgers
Journal:  Exp Clin Cardiol       Date:  2002

4.  The extracellular matrix in hibernating myocardium--a significant factor causing structural defects and cardiac dysfunction.

Authors:  A Elsässer; M Schlepper; R Zimmermann; K D Müller; R Strasser; W P Klövekorn; J Schaper
Journal:  Mol Cell Biochem       Date:  1998-09       Impact factor: 3.396

Review 5.  Molecular and cellular basis of viable dysfunctional myocardium.

Authors:  Marina Bayeva; Konrad Teodor Sawicki; Javed Butler; Mihai Gheorghiade; Hossein Ardehali
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

6.  Characterization of a hyperpolarization-activated current in dedifferentiated adult rat ventricular cells in primary culture.

Authors:  N Farès; P Bois; J Lenfant; D Potreau
Journal:  J Physiol       Date:  1998-01-01       Impact factor: 5.182

Review 7.  Multimodality Imaging of Myocardial Viability.

Authors:  Kinjan Parikh; Alana Choy-Shan; Munir Ghesani; Robert Donnino
Journal:  Curr Cardiol Rep       Date:  2021-01-04       Impact factor: 2.931

Review 8.  Structural aspects of the chronic hibernating myocardium in man.

Authors:  M Borgers; J Ausma
Journal:  Basic Res Cardiol       Date:  1995 Jan-Feb       Impact factor: 17.165

Review 9.  Remodeling and dedifferentiation of adult cardiomyocytes during disease and regeneration.

Authors:  Marten Szibor; Jochen Pöling; Henning Warnecke; Thomas Kubin; Thomas Braun
Journal:  Cell Mol Life Sci       Date:  2013-12-10       Impact factor: 9.261

10.  Dedifferentiated cardiomyocytes from chronic hibernating myocardium are ischemia-tolerant.

Authors:  J Ausma; F Thoné; G D Dispersyn; W Flameng; J L Vanoverschelde; F C Ramaekers; M Borgers
Journal:  Mol Cell Biochem       Date:  1998-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.